• Meta-Analysis Compares TAS-102 and Regorafenib Sequencing in Later-Line mCRC

    A systematic review and meta-analysis compared efficacy and safety of TAS-102 followed by regorafenib versus the reverse sequence in patients with metastatic colorectal cancer who had previously failed chemotherapy. (Chin Clin Oncol)